drugset / Trial / NCT03220191

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

NCT03220191

Phase 1 Completed 12 enrolled Pfizer
SequentialOpen-labelBasic science

Summary

to evaluate the effect of the PPI (rabeprazole) on the PK of a potential commercial tablet formulation of palbociclib

Timeline

Start
2017-07-21
Primary completion
2017-09-03
Completion
2017-09-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule
Subject Rabeprazole Small molecule

Indications

No indication recorded.